43 research outputs found
Combined Serological, Genetic, and Inflammatory Markers Differentiate Non-IBD, Crohnʼs Disease, and Ulcerative Colitis Patients:
Previous studies have demonstrated that serological markers can assist in diagnosing inflammatory bowel disease (IBD). In this study, we aim to build a diagnostic tool incorporating serological markers, genetic variants, and markers of inflammation into a computational algorithm to examine patterns of combinations of markers to (1) identify patients with IBD and (2) differentiate patients with Crohn’s disease (CD) from ulcerative colitis (UC)
999 Classification of non-IBD, Crohn's Disease and Ulcerative Colitis in a Young Patient Population Using a Multi-Marker Diagnostic Panel
1029 Serological and Inflammatory IBD Marker Prevalence As Function of Age in a Large Cohort of Patients Presenting IBD-Like Gastrointestinal Symptoms
108 Blood MicroRNA (miRNA) Expression Patterns Can Identify Inflammatory Bowel Disease (IBD) Patients With Dysplasia and Cancer
Su1169 Genetic Variants and Markers of Inflammation Help to Identify IBD Patients With Low Serology
Mo1322 Serological and Genetic Markers As Predictors of Complicated Disease in Patients With Crohn's Disease
166 Combined Serologic, Genetic, and Inflammatory Markers Can Accurately Differentiate Non-IBD, Crohn's Disease, and Ulcerative Colitis Patients
Sa1200 Presence and Concentration of OmpC As a Risk Factor for Developing Antibodies to Infliximab (ATI): Implications for Selecting Patients With Inflammatory Bowel Disease (IBD) for Combination Therapy
A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's Disease
Prediction of primary non-response [PNR] to anti-tumour necrosis factors [TNFs] in inflammatory bowel disease [IBD] is direly needed to select the optimal therapeutic class for a given patient. We developed a matrix-based prediction tool to predict response to infliximab [IFX] in Crohn's disease [CD] patients.status: publishe